Related Experiment Video
Updated: May 7, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
[Biobanking in clinical trials involving multiple sclerosis patients]
E M Kamenskikh1, A Yu Krygina1, S Ch Gomboeva1
1Siberian State Medical University, Tomsk, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|August 23, 2024
Summary
Biobanking is crucial for high-quality omics research in multiple sclerosis (MS) studies. Standardizing biomaterial handling through biobanks enhances research reliability and enables large-scale, collaborative MS investigations.
Area of Science:
- Precision medicine
- Omics research (genomics, microbiomics, metabolomics)
- Biomaterial analysis
Context:
- Multiple sclerosis (MS) pathogenesis research demands advanced analytical tools.
- Omics research, including genomics, microbiomics, and metabolomics, requires meticulous preanalytical work with biomaterials.
- Biobanking offers a standardized approach to biomaterial handling for consistent research outcomes.
Purpose:
- To analyze biobanking technologies in multiple sclerosis (MS) research.
- To highlight the importance of preanalytical work in omics studies.
- To share experiences of collaboration between MS research centers and biobanks.
Summary:
- Biobanking standardizes biomaterial handling, crucial for sensitive omics research in multiple sclerosis (MS).
- This approach ensures the quality and objectivity of results in MS pathogenesis studies.
- Collaboration with biobanks facilitates multicenter and long-term prospective studies involving numerous patients.
Impact:
- Enhances the reliability and comparability of multiple sclerosis research findings.
- Facilitates large-scale, multicenter, and long-term prospective studies in MS.
- Supports advancements in understanding MS pathogenesis through standardized, high-quality data.
Related Concept Videos
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...